Uğur ÖZKAN

Uğur ÖZKAN is an active Turkish cardiologist specializing in interventional cardiology and cardiovascular research with a focus on inflammatory mechanisms in cardiac disease. His academic work centers at institutions implied through Turkish medical journals and conferences, particularly within cardiology departments.

His research interests prominently feature valvular heart disease (especially aortic stenosis and bioprosthetic valve outcomes), Takotsubo syndrome pathogenesis and management, inflammatory biomarkers in arrhythmogenesis, and cardio-renal interactions during interventions. Recent work demonstrates particular expertise in triglyceride-glucose index applications, pheochromocytoma-induced cardiac dysfunction, and septic complications in infective endocarditis.

Analysis of his 15 most recent publications (2023-2024) reveals strong emphasis on translational cardiology bridging clinical practice and pathophysiological mechanisms. Key trends include biomarker validation for risk stratification (Systemic Immune-Inflammation Index, Triglyceride-Glucose Index), pharmacological cardioprotection (SGLT2 inhibitors), and management challenges in geriatric and special-population cardiology.

His scholarly output includes first-author publications in major cardiology journals (Balkan Medical Journal, Polish Heart Journal, Journal of Geriatric Cardiology), book chapters on atrial fibrillation and anticoagulation, and presentations at national conferences including the International Trakya Family Medicine Congress.

Dr. ÖZKAN's educational background includes a doctoral degree completed in 2017 following bachelor's studies concluded in 2011, with continuous research activity evidenced by 25+ indexed publications between 2018-2024. His work frequently addresses clinical dilemmas in cardiac device implantation, myocardial infarction management during pandemics, and multidisciplinary approaches to complex cardiac conditions.